In yesterday’s Wall Street session, Molecular Templates Inc. (NASDAQ:MTEM) shares traded at $0.45, up 8.70% from the previous session.
7 analysts cover Molecular Templates Inc. (NASDAQ:MTEM), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $18.00 and a low of $1.00, we find $9.00. Given the previous closing price of $0.41, this indicates a potential upside of 2095.12 percent. MTEM stock price is now -10.80% away from the 50-day moving average and -56.57% away from the 200-day moving average. The market capitalization of the company currently stands at $24.56M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 5. Brokers who have rated the stock have averaged $8.30 as their price target over the next twelve months.
With the price target of $12, BofA Securities recently initiated with Buy rating for Molecular Templates Inc. (NASDAQ: MTEM). On February 01, 2021, UBS recently initiated its ‘Neutral’ rating on the stock quoting a target price of $13, while ‘Jefferies’ rates the stock as ‘Buy’.
In other news, McLennan Sean, insider bought 30,000 shares of the company’s stock on Jun 16. The stock was bought for $24,477 at an average price of $0.82. Upon completion of the transaction, the insider now directly owns 30,000 shares in the company, valued at $13500.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 15, Director LALANDE KEVIN M. bought 62,000 shares of the business’s stock. A total of $55,180 was incurred on buying the stock at an average price of $0.89. This leaves the insider owning 222,000 shares of the company worth $99900.0. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MTEM stock. A new stake in Molecular Templates Inc. shares was purchased by BALYASNY ASSET MANAGEMENT LLC during the first quarter worth $11,000. Y-INTERCEPT (HONG KONG) LTD invested $6,000 in shares of MTEM during the first quarter. In the first quarter, AMALGAMATED FINANCIAL CORP. acquired a new stake in Molecular Templates Inc. valued at approximately $3,000. In total, there are 93 active investors with 74.50% ownership of the company’s stock.
On Tuesday morning Molecular Templates Inc. (NASDAQ: MTEM) stock kicked off with the opening price of $0.4099. During the past 12 months, Molecular Templates Inc. has had a low of $0.31 and a high of $4.24. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.70, and a quick ratio of 1.70. The fifty day moving average price for MTEM is $0.4968 and a two-hundred day moving average price translates $1.0152 for the stock.
The latest earnings results from Molecular Templates Inc. (NASDAQ: MTEM) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.44, beating analysts’ expectations of -$0.48 by 0.04. This compares to -$0.54 EPS in the same period last year. The company reported revenue of $4.24 million for the quarter, compared to $2.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 78.23 percent. For the current quarter, analysts expect MTEM to generate $3.3M in revenue.
Molecular Templates Inc.(MTEM) Company Profile
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
